Disruptions in the function of certain neurotransmitters, such as AChE, combined with reduced release of BDNF in type 2 diabetes mellitus, significantly heighten the risk of CI in affected individuals (Ahmad et al., 2022). This evidence concerns the gene ACHE and type 2 diabetes mellitus.